At the news
? BULLISHIMPACT 7/10 8-K filed Apr 21, 2026 at 16:01 ET
Foghorn Therapeutics presented new preclinical data at AACR 2026 showing promising results across its pipeline, including complete tumor regression with FHD-909 in combination with anti-PD1 and strong efficacy in multiple degrader programs. The company also announced its ongoing collaboration with Lilly.
- FHD-909 in combination with anti-PD1 demonstrated complete and durable tumor regression in preclinical models
- Selective CBP degrader FHT-171 showed strong anti-tumor activity in ER+ breast cancer models
- Selective EP300 degrader outperformed clinical benchmark in multiple myeloma models
- Robust degradation achieved with cereblon-based selective ARID1B degraders
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access